Department of Health
From 1 March 2022, eculizumab (Soliris®) will be available under the Section 100 Highly Specialised Drugs (HSD) program of the Pharmaceutical Benefits Scheme. Until now, we have subsidised Soliris® under the Life Saving Drugs Program.
This change applies to all existing patients with paroxysmal nocturnal haemoglobinuria (PNH).
If you are a patient with PNH, make an appointment to see your treating physician to transition you to the new program.
If you are a prescriber treating patients with PNH, read our fact sheet to find out how to transition your patients.
For more details about the changes to Soliris® access for PNH patients, see our fact sheets for:
/Media Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
